Percentage inhibition against antigen-induced IL-4 production in RBL-2H3 cells at 0 uM concentration
|
Rattus norvegicus
|
0.0
%
|
|
Percentage inhibition against antigen-induced IL-4 production in RBL-2H3 cells at 10 uM concentration
|
Rattus norvegicus
|
89.4
%
|
|
Percentage inhibition against antigen-induced IL-4 production in RBL-2H3 cells at 3 uM concentration
|
Rattus norvegicus
|
41.6
%
|
|
Percentage inhibition against antigen-induced IL-4 production in RBL-2H3 cells at 30 uM concentration
|
Rattus norvegicus
|
99.2
%
|
|
Percentage inhibition against antigen-induced TNF-alpha production in RBL-2H3 cells at 0 uM concentration
|
Rattus norvegicus
|
0.0
%
|
|
Percentage inhibition against antigen-induced TNF-alpha production in RBL-2H3 cells at 10 uM concentration
|
Rattus norvegicus
|
89.0
%
|
|
Percentage inhibition against antigen-induced TNF-alpha production in RBL-2H3 cells at 3 uM concentration
|
Rattus norvegicus
|
25.0
%
|
|
Percentage inhibition against antigen-induced TNF-alpha production in RBL-2H3 cells at 30 uM concentration
|
Rattus norvegicus
|
101.3
%
|
|
Inhibition of glycogen synthase kinase 3
|
None
|
800.0
nM
|
|
Inhibition of FabG in presence of NADPH
|
Plasmodium falciparum
|
800.0
nM
|
|
Peroxynitrite scavenging activity assessed as inhibition of DHR oxidation
|
None
|
300.0
nM
|
|
Peroxynitrite scavenging activity assessed as inhibition of DHR oxidation in presence of NaHCo3
|
None
|
640.0
nM
|
|
Inhibition of COX2 in I1-10-stimulated bone marrow derived mast cells
|
None
|
80.0
%
|
|
Inhibition of COX2 at 100 uM by scintillation proximity assay
|
None
|
30.0
%
|
|
Inhibition of COX2
|
None
|
100.0
ug.mL-1
|
|
Inhibition of COX2 in LPS-stimulated bone marrow derived mast cells
|
None
|
2.5
ug.mL-1
|
|
Inhibition of bovine thymus p56LCK-catalyzed phosphorylation of angiotensin 1 by SDS-PAGE
|
Bos taurus
|
10.0
ug.mL-1
|
|
Inhibition of bovine thymus p56-LCK protein tyrosine kinase activity
|
Bos taurus
|
4.0
ug.mL-1
|
|
Inhibition of Saccharomyces cerevisiae fatty acid synthase
|
Saccharomyces cerevisiae
|
9.0
ug.mL-1
|
|
Antifungal activity against Candida albicans ATCC 90028
|
Candida albicans
|
50.0
ug.mL-1
|
|
Antifungal activity against Cryptococcus neoformans ATCC 90113
|
Cryptococcus neoformans
|
50.0
ug.mL-1
|
|
Inhibition of p56 lck
|
None
|
10.0
ug.mL-1
|
|
Cytotoxicity against human HL60 cells after 3 days by MTT assay
|
Homo sapiens
|
10.0
ug.mL-1
|
|
Cytotoxicity against human SW1573 cells after 3 days by MTT assay
|
Homo sapiens
|
10.0
ug.mL-1
|
|
Cytotoxicity against human CEM cells after 3 days by MTT assay
|
Homo sapiens
|
10.0
ug.mL-1
|
|
Antioxidant activity assessed as DPPH free radical scavenging activity
|
None
|
7.2
ug.mL-1
|
|
Antioxidant activity in human HL60 cells assessed as reduction of cytochrome-c release
|
Homo sapiens
|
12.1
ug.mL-1
|
|
Inhibition of xanthine oxidase assessed as decrease in uric acid production by spectrophotometry
|
None
|
550.0
nM
|
|
Inhibition of COX2 at 2.5 ug/mL
|
None
|
80.0
%
|
|
Inhibition of COX1 at 2.5 ug/mL
|
None
|
75.0
%
|
|
Inhibition of human salivary alpha-amylase
|
Homo sapiens
|
88.8
%
|
|
Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 30 uM after 72 hrs
|
Mus musculus
|
76.7
%
|
|
Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 10 uM after 72 hrs
|
Mus musculus
|
38.1
%
|
|
Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 3 uM after 72 hrs
|
Mus musculus
|
13.5
%
|
|
Inhibition of theophylline-stimulated melanogenesis in mouse B16-4A5 cells at 1 uM after 72 hrs
|
Mus musculus
|
6.2
%
|
|
Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 1 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay
|
Mus musculus
|
-4.8
%
|
|
Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 3 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay
|
Mus musculus
|
-4.9
%
|
|
Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 10 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay
|
Mus musculus
|
4.0
%
|
|
Toxicity in mouse B16-4A5 cells assessed as inhibition of cell proliferation at 30 uM in presence of 1 mM theophylline after 72 hrs by WST8 dye reduction assay
|
Mus musculus
|
23.4
%
|
|
Inhibition of mushroom tyrosinase at 1 uM
|
Agaricus bisporus
|
6.4
%
|
|
Inhibition of mushroom tyrosinase at 3 uM
|
Agaricus bisporus
|
7.1
%
|
|
Inhibition of mushroom tyrosinase at 10 uM
|
Agaricus bisporus
|
9.2
%
|
|
Inhibition of mushroom tyrosinase at 30 uM
|
Agaricus bisporus
|
12.1
%
|
|
Inhibition of mushroom tyrosinase at 100 uM
|
Agaricus bisporus
|
17.6
%
|
|
Inhibition of rat liver DNA topoisomerase 1 preincubated before addition of DNA
|
Rattus norvegicus
|
660.0
nM
|
|
Inhibition of Influenza A PR/8/34 H1N1 virus neuraminidase activity by MUN-ANA substrate based fluorimetric assay
|
Influenza A virus (A/Puerto Rico/8/1934(H1N1))
|
9.65
ug.mL-1
|
|
Inhibition of human CYP1B1 by EROD assay
|
Homo sapiens
|
79.0
nM
|
|
Inhibition of NOX4 expressed in HEK293 FS cells at 10 uM assessed as H2O2 production by H2O2/Tyr/LPO assay
|
None
|
106.0
%
|
|
Inhibition of NOX4 expressed in HEK293 FS cells assessed as H2O2 production by H2O2/Tyr/LPO assay
|
None
|
850.0
nM
|
|
Cytotoxicity against human free style HEK293 cells after 72 hrs
|
Homo sapiens
|
-4.47
%
|
|
Inhibition of NOX4 expressed in HEK293 FS cells at 10 uM assessed as H2O2 production by H2O2/Tyr/LPO assay substituted with 3 uM H2O2
|
None
|
110.36
%
|
|
Cytotoxicity against human HepG2 cells by MTT assay
|
Homo sapiens
|
7.36
ug.mL-1
|
|
Cytotoxicity against human Hep3B cells by MTT assay
|
Homo sapiens
|
8.03
ug.mL-1
|
|
Cytotoxicity against human Ca9-22 cells by MTT assay
|
Homo sapiens
|
8.55
ug.mL-1
|
|
Cytotoxicity against human A549 cells by MTT assay
|
Homo sapiens
|
10.23
ug.mL-1
|
|
Cytotoxicity against human MCF7 cells by MTT assay
|
Homo sapiens
|
9.5
ug.mL-1
|
|
Cytotoxicity against human MDA-MB-231 cells by MTT assay
|
Homo sapiens
|
9.65
ug.mL-1
|
|
Antiaggregatory activity in human platelets assessed as inhibition of collagen-induced platelet aggregation by aggregometry
|
Homo sapiens
|
2.56
ug.mL-1
|
|
Antiaggregatory activity in human platelets assessed as inhibition of thrombin-induced platelet aggregation by aggregometry
|
Homo sapiens
|
50.0
ug.mL-1
|
|
Inhibition of CYP1A1 EROD activity assessed as inhibition of deethylation of 7-ethoxyresorufin to resorufin
|
None
|
890.0
nM
|
|
Inhibition of CYP1B1 EROD activity assessed as inhibition of deethylation of 7-ethoxyresorufin to resorufin
|
None
|
56.0
nM
|
|
Inhibition of Xanthomonas oryzae pv. oryzae KS-1-21 uridyltransferase domain of GlmU activity by ion-pair reverse-phase HPLC analysis
|
Xanthomonas oryzae pv. oryzae
|
810.0
nM
|
|
Competitive inhibition of Xanthomonas oryzae pv. Oryzae KS-1-21 GlmU using 0.25 to 0.05 mM GlcNAc-1-p and 500 uM UTP by Lineweaver-Burk plot analysis
|
Xanthomonas oryzae pv. oryzae
|
440.0
nM
|
|
Uncompetitive inhibition of Xanthomonas oryzae pv. Oryzae KS-1-21 GlmU using varying concentration of UTP and 500 uM GlcNAc-1-p by Lineweaver-Burk plot analysis
|
Xanthomonas oryzae pv. oryzae
|
990.0
nM
|
|
Inhibition of human recombinant MMP12 catalytic domain incubated for 20 mins by fluorimetric assay
|
Homo sapiens
|
980.0
nM
|
|
Inhibition of human recombinant MMP2 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay
|
Homo sapiens
|
30.0
%
|
|
Inhibition of human recombinant MMP3 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay
|
Homo sapiens
|
30.0
%
|
|
Inhibition of human recombinant MMP9 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay
|
Homo sapiens
|
30.0
%
|
|
Inhibition of human recombinant MMP12 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay
|
Homo sapiens
|
30.0
%
|
|
Inhibition of human recombinant MMP13 catalytic domain at 10 uM incubated for 20 mins by fluorimetric assay
|
Homo sapiens
|
30.0
%
|
|
Antioxidant activity assessed as DPPH free radical scavenging activity
|
None
|
44.18
ug.mL-1
|
|
Antioxidant activity assessed as superoxide radical scavenging activity
|
None
|
31.01
ug.mL-1
|
|
Antioxidant activity of the compound assessed as inhibition of lipid peroxidation
|
None
|
134.1
ug.mL-1
|
|
Antioxidant activity in erythrocytes assessed as inhibition of hemolysis
|
None
|
122.0
ug.mL-1
|
|
Cytotoxicity against TRAIL-resistant human AGS cells assessed as inhibition of cell viability at 17.5 uM after 24 hrs by fluorescence assay in presence of 100 ng/ml TRAIL relative to in absence of TRAIL
|
Homo sapiens
|
48.0
%
|
|
Inhibition of electric eel AChE at 2 mg/ml by Ellman's method
|
Electrophorus electricus
|
13.58
%
|
|
Inhibition of horse BChE at 2 mg/ml by Ellman's method
|
Equus caballus
|
0.42
%
|
|
Inhibition of alpha-glucosidase (unknown origin) using para-nitrophenyl-alpha-D-glucopyranoside as substrate incubated at 50 to 300 ug/ml for 15 min prior to substrate addition measured after 15 min by spectrophotometric analysis
|
Homo sapiens
|
99.89
%
|
|
Antioxidant activity assessed as as DPPH radical scavenging activity after 30 min by spectrophotometry
|
None
|
0.99
ug.mL-1
|
|
Inhibition of alpha-glucosidase (unknown origin) using para-nitrophenyl-alpha-D-glucopyranoside as substrate incubated for 15 min prior to substrate addition measured after 15 min by spectrophotometric analysis
|
Homo sapiens
|
5.96
ug.mL-1
|
|
Antifungal activity against Verticillium dahliae assessed as inhibition of mycelial radial growth measured after 350 hr
|
Verticillium dahliae
|
7.0
ug.mL-1
|
|
Antiamoebic activity against Entamoeba histolytica
|
Entamoeba histolytica
|
17.8
ug.mL-1
|
|
Insecticidal activity against third-instar Spodoptera exigua larvae assessed as inhibition of body weight increase at 16 g/l measured from 24 hr to 48 hr
|
Spodoptera exigua
|
66.85
%
|
|
Insecticidal activity against third-instar Spodoptera exigua larvae assessed as inhibition of body weight increase at 8 g/l measured from 24 hr to 48 hr
|
Spodoptera exigua
|
56.82
%
|
|
Insecticidal activity against third-instar Spodoptera exigua larvae assessed as inhibition of body weight increase at 4 g/l measured from 24 hr to 48 hr
|
Spodoptera exigua
|
49.63
%
|
|
Insecticidal activity against third-instar Spodoptera exigua larvae assessed as inhibition of body weight increase at 2 g/l measured from 24 hr to 48 hr
|
Spodoptera exigua
|
42.68
%
|
|
Insecticidal activity against third-instar Spodoptera exigua larvae assessed as inhibition of body weight increase at 1 g/l measured from 24 hr to 48 hr
|
Spodoptera exigua
|
37.96
%
|
|
Antinociceptive activity Swiss albino Mus musculus (mouse) assessed as inhibition of formalin-induced paw licking at 10 mg/kg, po administered 60 min prior to formalin-challenge measured from 15 to 30 min relative to control
|
Mus musculus
|
48.64
%
|
|
Antinociceptive activity Swiss albino Mus musculus (mouse) assessed as inhibition of formalin-induced paw licking at 10 mg/kg, po administered 60 min prior to formalin-challenge measured up to 5 min relative to control
|
Mus musculus
|
40.31
%
|
|
Antinociceptive activity in Swiss albino Mus musculus (mouse) assessed as inhibition of acetic acid-induced writhing at 10 mg/kg, po administered 1 hr prior to acetic acid-challenge measured up to 20 min relative to control
|
Mus musculus
|
55.35
%
|
|
Anti-inflammatory activity in Swiss albino Mus musculus (mouse) assessed as inhibition of cotton pellet-induced granuloma formation at 10 mg/kg, po administered QD for 5 days measured at 1 hr post-last dose relative to control
|
Mus musculus
|
36.98
%
|
|
Anti-inflammatory activity in Swiss albino Mus musculus (mouse) assessed as inhibition of carrageenan-induced paw edema at 10 mg/kg, ip administered 30 min prior to carrageenan-challenge measured after 5 hr relative to control
|
Mus musculus
|
50.0
%
|
|
Inhibition of recombinant FLT3 (unknown origin) by TR-FRET assay
|
Homo sapiens
|
830.0
nM
|
|
Antioxidant activity assessed as inhibition of lipid peroxidation activity after 15 mins by MDA assay
|
None
|
149.7
ug.mL-1
|
|
Hemolysis of human erythrocytes after 30 mins by spectrophotometry
|
Homo sapiens
|
107.28
ug.mL-1
|
|
Antioxidant activity assessed as DPPH scavenging activity after 30 mins by UV-visible spectrophotometry
|
None
|
44.18
ug.mL-1
|
|
Antioxidant activity assessed as superoxide radical scavenging activity after 5 mins by spectrophotometry
|
None
|
31.01
ug.mL-1
|
|
Inhibition of human recombinant aldose reductase
|
Homo sapiens
|
600.0
nM
|
|
Inhibition of bovine lens aldose reductase using DL-glyceraldehyde as substrate assessed as NADPH oxidation measured for 10 mins by spectrophotometric analysis
|
Bos taurus
|
754.0
nM
|
|
Inhibition of MPO release in zymosan-stimulated human neutrophils by luminol-dependent chemiluminescence assay
|
Homo sapiens
|
100.0
%
|
|
Inhibition of oxidative burst in PMA-stimulated human neutrophils assessed as inhibition of HOCl-induced oxidation of APF after 6 mins by fluorescence assay
|
Homo sapiens
|
900.0
nM
|
|
Antiviral activity against HIV-1 3B infected in human C8166 cells assessed as inhibition of virus-induced cytopathogenicity by measuring syncytial cell number after 3 days by inverted microscopic analysis
|
Human immunodeficiency virus 1
|
2.48
ug.mL-1
|
|
Inhibition of His6-tagged HIV-1 integrase assessed as decrease in integrase-Flag-LEDGF/p75 interaction preincubated with enzyme for 30 mins followed by addition of Flag-LEDGF/p75 for 1 hr by AlphaScreen assay
|
Human immunodeficiency virus 1
|
450.0
nM
|
|
Inhibition of NO production in LPS-stimulated mouse RAW264.7 cells pre-incubated for 2 hrs before LPS stimulation for 24 hrs by Griess assay method
|
Mus musculus
|
210.0
nM
|
|
Inhibition of alpha glucosidase (unknown origin) at 0.5 mg/ml
|
Homo sapiens
|
36.0
%
|
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 1 uM after 72 hrs by microplate reader analysis relative to control
|
Mus musculus
|
6.2
%
|
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 3 uM after 72 hrs by microplate reader analysis relative to control
|
Mus musculus
|
13.5
%
|
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 10 uM after 72 hrs by microplate reader analysis relative to control
|
Mus musculus
|
38.1
%
|
|
Inhibition of melanogenesis in theophylline-stimulated mouse B16-4A5 cells at 30 uM after 72 hrs by microplate reader analysis relative to control
|
Mus musculus
|
76.7
%
|
|
Inhibition of mushroom tyrosinase using L-DOPA as substrate assessed as dopaquinone production at 10 uM after 5 mins by microplate reader analysis relative to control
|
Agaricus bisporus
|
11.4
%
|
|
Inhibition of mushroom tyrosinase using L-DOPA as substrate assessed as dopaquinone production at 100 uM after 5 mins by microplate reader analysis relative to control
|
Agaricus bisporus
|
33.5
%
|
|
Inhibition of plasmin (unknown origin) at 100 uM after 18 hrs by arianor mahogany dye-based fibrin plate assay relative to control
|
Homo sapiens
|
28.7
%
|
|
Binding affinity to TTR (unknown origin) by isothermal titration calorimetric analysis
|
Homo sapiens
|
70.0
nM
|
|
Inhibition of xanthine oxidase (unknown origin) using xanthine as substrate at 33 to 100 umol/L after 10 mins by HPLC method relative to control
|
Homo sapiens
|
50.0
%
|
|
Anti-platelet activity in rat platelet rich plasma assessed as inhibition of ADP and calcium-induced platelet aggregation at 100 uM pre-incubated at 37 degC for 10 mins and measured 30 mins after ADP and calcium addition
|
Rattus norvegicus
|
26.55
%
|
|
Inhibition of human recombinant carbonic anhydrase 7 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay
|
Homo sapiens
|
4.7
nM
|
|
Inhibition of human recombinant carbonic anhydrase 12 preincubated for 15 mins at room temperature/6 hrs at 4 deg C by stopped-flow CO2 hydration assay
|
Homo sapiens
|
60.3
nM
|
|
Inhibition of human recombinant carbonic anhydrase 4
|
Homo sapiens
|
293.0
nM
|
|
Inhibition of recombinant human AKR1B10 expressed in human HCT116 cells assessed as reduction in daunorubicinol production using daunorubicin as substrate at 20 uM incubated for 4 to 8 hrs by UHPLC based transient transfection assay
|
Homo sapiens
|
33.0
%
|
|
Antitrypanosomal activity against Trypanosoma brucei rhodesiense STIB 900 after 72 hrs by alamar blue staining based fluorescence analysis
|
Trypanosoma brucei rhodesiense
|
3.7
ug.mL-1
|
|
Cytotoxicity against rat L6 cells after 72 hrs by alamar blue staining based fluorescence analysis
|
Rattus norvegicus
|
9.4
ug.mL-1
|
|
Antileishmanial activity against Leishmania donovani MHOM/ET/67/L82 after 72 hrs by Alamar blue dye based fluorescence analysis
|
Leishmania donovani
|
0.8
ug.mL-1
|
|
Antitrypanosomal activity against trypomastigote forms of Trypanosoma cruzi Tulahuen C2C4 infected in rat L6 cells after 96 hrs by photometric method
|
Trypanosoma cruzi
|
21.4
ug.mL-1
|
|
Inhibition of Bcl-2 (unknown origin) using FAM-Bid peptide as substrate at 50 uM by fluorescence polarization-based assay
|
Homo sapiens
|
46.0
%
|
|
Inhibition of Bcl-XL (unknown origin) using FAM-Bid peptide as substrate at 50 uM by fluorescence polarization-based assay
|
Homo sapiens
|
49.0
%
|
|
Inhibition of sucrose loaded POPC/POPE/POPS/PtdIns(3,4,5)P3 (59:20:20:1) liposome binding to eGFP-fused PDK1 PH domain (unknown origin) expressed in Escherichia coli BL21 at 20 uM after 10 mins by fluorescence spectrophotometry based pull down assay relative to control
|
Homo sapiens
|
31.12
%
|
|
Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-stimulated NO production at 5 uM by ELISA relative to control
|
Mus musculus
|
19.5
%
|
|
Inhibition of recombinant human CYP1B1 expressed in supersomes using ethoxyresorufin as substrate preincubated for 5 mins followed by substrate addition in presence of NADPH by fluorimetric analysis
|
Homo sapiens
|
360.0
nM
|
|
Inhibition of HFIP-pretreated amyloid beta (1 to 42) (unknown origin) self-induced aggregation at 20 uM incubated for 24 hrs under dark condition by thioflavin-T based fluorometric assay relative to control
|
Homo sapiens
|
86.5
%
|
|
Inhibition of Saccharomyces cerevisiae alpha-glucosidase using p-nitro-phenyl-alpha-D-glucopyranoside as substrate at 200 uM preincubated with enzyme followed by substrate addition measured after 10 mins for every 2.5 to 5 mins relative to control
|
Saccharomyces cerevisiae
|
99.6
%
|
|
Inhibition of DPP4 (unknown origin) using Gly-Pro-AMC as substrate preincubated for 4 secs followed by substrate addition and measured after 30 mins by luminescence assay
|
Homo sapiens
|
120.0
nM
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging
|
Homo sapiens
|
1.01
%
|
|
Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 1 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control
|
Homo sapiens
|
19.8
%
|
|
Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 5 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control
|
Homo sapiens
|
40.75
%
|
|
Inhibition of human recombinant full length PTP1B expressed in Escherichia coli cells at 10 uM using pNPP as substrate preincubated with enzyme for 5 mins followed by incubation with substrate for 10 mins by spectrophotometry analysis relative to control
|
Homo sapiens
|
39.92
%
|
|
Inhibition of human recombinant CK2 expressed in Escherichia coli using RRRADDSDDDDD as substrate after 10 mins in presence of [gamma-32P]ATP
|
Homo sapiens
|
500.0
nM
|
|
Inhibition of PKC in rat brain homogenate at 50 uM using FKKSFKL-NH2 as substrate preincubated for 10 mins followed by substrate addition and measured after 5 mins in presence of [gamma-32P]ATP by liquid scintillation counting analysis relative to control
|
Rattus norvegicus
|
70.0
%
|
|
Inhibition of F1F0-ATP synthase in Escherichia coli after 60 mins relative to control
|
Escherichia coli
|
0.0
%
|
|
Inhibition of T0901317-induced LXR-alpha/beta transactivation in mouse RAW264.7 cells assessed as reduction in ABCA1 mRNA expression at 25 uM after 3 hrs by RT-PCR method relative to control
|
Mus musculus
|
41.0
%
|
|
Inhibition of T0901317-induced LXR-alpha/beta transactivation in mouse RAW264.7 cells assessed as reduction in ABCA1 mRNA expression at 50 uM after 3 hrs by RT-PCR method relative to control
|
Mus musculus
|
64.0
%
|
|
Antihyperlipidemic activity in ethanol-induced steatosis C57BL/6 mouse model assessed as inhibition of serum triacylglycerol level at 50 mg/kg, po administered daily through oral gavage for 2 weeks by colorimetric method relative to control
|
Mus musculus
|
22.0
%
|
|
Antihyperlipidemic activity in ethanol-induced steatosis C57BL/6 mouse model assessed as inhibition of serum LDL cholesterol level at 50 mg/kg, po administered daily through oral gavage for 2 weeks by colorimetric method relative to control
|
Mus musculus
|
52.0
%
|
|
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate
|
Severe acute respiratory syndrome coronavirus 2
|
-3.027
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.07
%
|
|
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging
|
Chlorocebus sabaeus
|
-0.07
%
|
|
In-vivo inhibition of ICR mouse beta-glucuronidase at 20 mg/kg, sc after 10 weeks relative to DMH alone
|
Mus musculus
|
14.9
%
|
|
In-vivo inhibition of ICR mouse beta-glucuronidase at 60 mg/kg, sc after 10 weeks relative to DMH alone
|
Mus musculus
|
21.3
%
|
|
Inhibition of human liver FBP1 at 200 uM incubated for 5 mins by fluorescence method relative to control
|
Homo sapiens
|
22.0
%
|
|
Inhibition of N-terminal GST-tagged recombinant human full length MNK2 expressed in baculovirus expression system at 10 uM incubated for 1 hr by Kinase Tracer 236 based LanthaScreen Eu kinase binding assay relative to control
|
Homo sapiens
|
70.0
%
|
|
Inhibition of N-terminal GST-tagged recombinant human full length MNK2 expressed in baculovirus expression system incubated for 1 hr by Kinase Tracer 236 based LanthaScreen Eu kinase binding assay relative to control
|
Homo sapiens
|
579.0
nM
|
|
Inhibition of GST-tagged recombinant human full length MNK1 expressed in insect cells at 10 uM relative to control
|
Homo sapiens
|
70.0
%
|
|
Inhibition of GST-tagged recombinant human full length MNK1 expressed in insect cells
|
Homo sapiens
|
179.0
nM
|
|
Inhibition of MNK1/MNK2 in human MV4-11 cells assessed as reduction in eIF4E phosphorylation reduction in eIF4E phosphorylation at 10 uM after 24 to 48 hrs by Western blot analysis
|
Homo sapiens
|
100.0
%
|
|
Inhibition of MNK1/MNK2 in human MOLM-13 cells assessed as reduction in eIF4E phosphorylation reduction in eIF4E phosphorylation at 10 uM after 24 to 48 hrs by Western blot analysis
|
Homo sapiens
|
100.0
%
|
|
Inhibition of biotinylated 5-(4-((Z)-3-Carboxy-3-hydroxyacryloyl)-4-(4-chlorobenzyl)piperidine-1-carbonyl)-2-((13,35-dioxo-39-((3aR,4R,6aS)-2-oxohexahydro-1H-thieno[3,4-d]imidazole-4-yl)-3,6,9,16,19,22,25,28,31-nonaoxa-12,34-diazanonatriacontyl)oxy)benzoic acid binding to Influenza A virus (A/California/07/2009(H1N1)) N-terminal GST-tagged polymerase acidic subunit N-terminal domain expressed in Escherichia coli BL21 (DE3) RIL cells measured after 120 mins by Alphascreen assay
|
Influenza A virus (A/California/07/2009(H1N1))
|
72.0
nM
|
|
Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells at 10 uM measured after 24 hrs by Griess reagent based assay relative to control
|
Mus musculus
|
54.6
%
|
|
Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL complex formation at 10 uM incubated for 15 mins in presence of cardiolipin by Trp-59 fluorescence assay relative to control
|
Homo sapiens
|
84.0
%
|
|
Inhibition of cytochrome c (unknown origin) assessed as reduction in cyt c-CL peroxidase activity at 10 uM up to 20 mins in presence of cardiolipin by Amplex red staining based fluorescence assay relative to control
|
Homo sapiens
|
71.0
%
|
|
Inhibition of cytochrome c (unknown origin) assessed as reduction reduction of cyt c from its ferric state to ferrous state at 10 uM incubated for 20 mins in presence of cardiolipin by UV-vis Spectrophotometric assay relative to control
|
Homo sapiens
|
32.0
%
|
|